Alector Inc (ALEC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-05. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 58/100 (HIGH), 9.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.49% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
- Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
- Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease Program
- Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
- Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
- Alector to Participate in Upcoming Healthcare Conferences
- Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
- GSK ends brain drug alliance with Alector
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Alector Inc.
Full ALEC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.